Quantification of lean tissue losses during cancer and HIV infection/AIDS

• Published in: Current opinion in clinical nutrition and metabolic care Vol. 14; no. 3; p. 261
• Main Authors: Thibault, Ronan, Cano, Noël, Pichard, Claude
• Format: Journal Article
• Language: English
• Published: England 01.05.2011
• Subjects: Acquired Immunodeficiency Syndrome - complications; Acquired Immunodeficiency Syndrome - pathology; Body Composition; Body Fluid Compartments - physiology; Cachexia - complications; Clinical Protocols; Humans; Malnutrition - complications; Muscle, Skeletal - pathology; Neoplasms - complications; Neoplasms - pathology; Obesity - complications; Prognosis; Sarcopenia - etiology
• ISSN: 1473-6519
• DOI: 10.1097/MCO.0b013e3283455d60

Cancer and HIV infection/AIDS are associated with an increased risk of undernutrition and cachexia. During the past decade, patients became older, frequently overweight or obese and sedentary, conditions which are likely to result in fat-free mass (FFM) loss. This review sustains the hypothesis that FFM measurement should be implemented in routine clinical practice, to optimize the management of cancer and AIDS, as well as disease-related undernutrition. Undernutrition and FFM loss are associated with worse clinical outcome and increased therapy toxicity in cancer and AIDS patients. The emergence of the concept of sarcopenic obesity in cancer patients, a condition associated with decreased survival, demonstrates the necessity to assess their body composition with easily available methods, such as dual energy X-ray absorptiometry, computerized tomography and bioelectrical impedance analysis. FFM measurement could be helpful for guiding the choice of both disease-specific and nutritional therapies and for evaluating their efficacy and putative toxicity. FFM measurement at different steps of disease course could allow improving the guidance and efficacy of both cancer and HIV/AIDS-specific and nutritional therapies. The repeated measurement of FFM could allow reducing undernutrition-related morbidity, mortality and global healthcare costs, and could improve response and tolerance towards therapy, and quality of life.